Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA
Subject: Renewal of licensing fee for the transgenic mouse strain, B-hIL2RASolicitation Number: 75N98026Q00467Notice Type: PRESOLNAICS: 51321Set-Aside: No Set aside usedNotice Published: 05-28-26Response Due: 06-08-26Agency: Department of Health and Human ServicesOffice: NATIONAL INSTITUTES OF HEALTHContact: John Burton This email address is being protected from spambots. You need JavaScript enabled to view it.Office Address: BETHESDA, MD 20892Place of Performance: MD 20892
Click for official SAM (FBO) notice, additional information, and accompanying attachments
The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed on regulatory T cells (Tregs). These cells can reduce the immune system’s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses. To support this research, MIB uses a transgenic mouse strain known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future human application. As a result, this mouse strain has proven invaluable in the MIB’s ongoing research program. The MIB is requesting to renew a licensing fee for transgenic mice, B-hIL2RA. B-hIL2RA transgenic mice.